INSPIRE NEWS
Inspire Newsroom
Inspire Launches Patient Voice AI: A Game-Changer in Life Sciences Insights
Inspire introduces Patient Voice AI, a cutting-edge tool that leverages AI and real patient discussions to provide actionable insights for life sciences teams. Designed to enhance research, clinical trial design, and market strategies, Patient Voice AI accelerates decision-making by up to 50%, ensuring a deeper understanding of patient needs.
New Survey Developed to Assess Sexual Health in Female Partners of Prostate Cancer Patients
Inspire collaborated with leading researchers to develop the SCIPPP-F questionnaire, a reliable tool assessing the sexual health of female partners of prostate cancer patients. Published in European Urology Oncology, the study highlights the impact of prostate cancer treatments on partners and underscores the importance of inclusive survivorship care.
Inspire Names Health Tech Leader Brett Kleger as New CEO
Inspire, the leading online health community and real-world data platform, has appointed Brett Kleger as CEO, effective June 5, 2024. Kleger brings extensive leadership experience, previously driving growth at Datacubed Health and DrugDev. Known for transforming companies into market leaders, Kleger aims to accelerate Inspire’s growth in real-world evidence, clinical trial recruitment, and patient engagement solutions.
Inspire and Takeda Researchers to Present Novel Study on Short Bowel Syndrome Patient Experience at DDW2024
Inspire has announced that it will present new research at Digestive Disease Week (DDW) 2024, unveiling insights from a mixed-method study on Short Bowel Syndrome (SBS) patient experience.
Inspire study to be presented at ISPOR 2024 reveals insights into chronic lymphocytic leukemia management
At ISPOR 2024, Inspire researchers will present groundbreaking findings in chronic lymphocytic leukemia (CLL) management. By integrating patient voices from Inspire’s community with medical data, the study highlights key unmet needs and long-term complications in CLL care, showcasing the value of real-world patient-centered insights.
New Inspire study with Takeda Pharmaceuticals sheds light on rare neuromuscular diseases
A new Inspire study presented at IgNS 2023 sheds light on the challenges faced by patients with Multifocal Motor Neuropathy (MMN) and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). In collaboration with Takeda Pharmaceuticals and leading experts, the study explores the patient journey, highlighting diagnostic challenges, treatment barriers, and unmet needs in education and care.